NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues
- PMID: 33223215
- PMCID: PMC7836329
- DOI: 10.1016/j.jhep.2020.09.006
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues
Keywords: COVID-19; Fatty liver; Liver injury; MAFLD; Mortality; NAFLD.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".J Hepatol. 2021 Feb;74(2):484-485. doi: 10.1016/j.jhep.2020.10.020. Epub 2020 Oct 29. J Hepatol. 2021. PMID: 33130185 Free PMC article. No abstract available.
Comment on
-
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.J Hepatol. 2020 Aug;73(2):451-453. doi: 10.1016/j.jhep.2020.03.044. Epub 2020 Apr 8. J Hepatol. 2020. PMID: 32278005 Free PMC article. No abstract available.
References
-
- Eslam M., Sanyal A.J., George J., International Consensus Panel MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. - PubMed
-
- Coronavirus Update (Live): 23,277,088 Cases and 806,013 Deaths from COVID-19 Virus Pandemic - Worldometer [Internet] https://www.worldometers.info/coronavirus/#countries Available at:
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
